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Abstract
Gene-level analysis of ImmunoChip or genome-wide association studies (GWAS) data has
not been previously reported for systemic sclerosis (SSc, scleroderma). The objective of
this study was to analyze genetic susceptibility loci in SSc at the gene level and to determine
if the detected associations were shared in African-American and White populations, using
data from ImmunoChip and GWAS genotyping studies. The White sample included 1833
cases and 3466 controls (956 cases and 2741 controls from the US and 877 cases and 725
controls from Spain) and the African American sample, 291 cases and 260 controls. In both
Whites and African Americans, we performed a gene-level analysis that integrates associa-
tion statistics in a gene possibly harboring multiple SNPs with weak effect on disease risk,
using Versatile Gene-based Association Study (VEGAS) software. The SNP-level analysis
was performed using PLINK v.1.07. We identified 4 novel candidate genes (STAT1,
FCGR2C, NIPSNAP3B, and SCT) significantly associated and 4 genes (SERBP1, PINX1,
TMEM175 and EXOC2) suggestively associated with SSc in the gene level analysis in
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White patients. As an exploratory analysis we compared the results on Whites with those
from African Americans. Of previously established susceptibility genes identified in Whites,
only TNFAIP3 was significant at the nominal level (p = 6.13x10-3) in African Americans in
the gene-level analysis of the ImmunoChip data. Among the top suggestive novel genes
identified in Whites based on the ImmunoChip data, FCGR2C and PINX1 were only nomi-
nally significant in African Americans (p = 0.016 and p = 0.028, respectively), while among
the top novel genes identified in the gene-level analysis in African Americans, UNC5C (p =
5.57x10-4) and CLEC16A (p = 0.0463) were also nominally significant in Whites. We also
present the gene-level analysis of SSc clinical and autoantibody phenotypes among Whites.
Our findings need to be validated by independent studies, particularly due to the limited
sample size of African Americans.
Introduction
Systemic sclerosis (SSc, scleroderma) [MIM 181750] is an autoimmune disease characterized
by three key features: (1) fibrosis of skin and internal organs, (2) a vasculopathy, and (3) auto-
antibody production. It is a multiorgan system disease with considerable phenotypic heteroge-
neity, resulting in a broad spectrum of disease severity. Several genome-wide, ImmunoChip,
and follow-up association studies were conducted to identify SNPs associated with SSc risk [1–
8]. All published studies implemented SNP-level analysis meaning that each SNP was analyzed
separately and those with genome wide level of statistical significance were deemed risk associ-
ated. SNP-level analysis is effective for identification of SNPs with strong individual effects,
however, it is underpowered to detect genes carrying multiple SNPs in the same gene of small
or medium effect size [9–11]. In the latter case, gene-level analysis can be beneficial because it
will detect genes with multiple small effect size SNPs as significant even if these genes do not
harbor any individual SNPs significant at the genome-wide level. However, a gene-level analy-
sis has never been applied to SSc.
In this study we performed a gene-level analysis focusing on the data generated by the
ImmunoChip platform. We compared results from the gene-level analysis with the results gen-
erated by traditional SNP-level analysis. We also performed a gene-level analysis of Immuno-
Chip and genome-wide association study (GWAS) data on of African-American SSc patients.
Although based on a relatively small group of patients, this study represents the first report of
genetic analysis of African Americans with SSc. The results of the gene-level analysis of SSc
clinical phenotypes (limited SSc (lcSSc) and diffuse SSc (dcSSc)) as well as autoantibody sub-
sets (anti-centromere autoantibodies (ACA) and anti-DNA topoisomerase I (ATA) autoanti-
bodies) among Whites are also presented.
Materials and methods
The study has been approved by the Institutional Review Boards of the participating US insti-
tutions, namely Boston University; Georgetown University; Medical University of South Caro-
lina; University of Alabama, Birmingham; University of California Los Angeles; University of
Michigan; University of Minnesota; University of Washington; University of Pittsburgh; Uni-
versity of Texas Health Science Center, Houston, University of Texas MD Anderson Cancer
Center, Houston, Geisel School of Medicine, Dartmouth College; and ethics committees of the
participating foreign institutions, namely Institute of Parasitology and Biomedicine Lo´pez-
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Race of the study participants was self-reported, and we used principal component analyses
to remove race outliers as described below. Details on the White population, genotyping and
quality control can be found in our previously published manuscript [7]. The White sample
included 956 cases and 2741 controls from the US and 877 cases and 725 controls from Spain,
after exclusion of individuals based on quality control (QC) (low call rates, non-European
ancestry, or relatedness). There were 1087 (59%) White patients with lcSSc, 574 (31%) with
dcSSc, 671 (37%) ACA-positive (ACA+), and 347 (19%) ATA+ patients (not all patients could
be classified into two distinct phenotypes or had either ACA or ATA antibodies).
The African American sample, after quality control measures, included 291 cases (56 men
and 235 women) and 260 controls (72 men and 188 women). In line with [12], the distribution
of clinical phenotypes and autoantibody subsets in the African American patient population
was markedly different from that in Whites. There were 82 (28%) patients with lcSSc, 201
(69%) with dcSSc, 21 (7%) ACA+, and 69 (24%) ATA+ among the African American cases (as
with Whites, not all patients could be classified into two distinct phenotypes or had either
ACA or ATA antibodies two patients were not tested for ACA and four for ATA).
ImmunoChip analysis: Genotyping was done by Illumina Infinium single-nucleotide poly-
morphism (SNP) microarray–ImmunoChip. Genotype calling was done using the Illumina
iScan System and the Genotyping Module (v.1.8.4) of the GenomeStudio Data Analysis soft-
ware. We applied the following criteria for QC: (1) individuals with call rate<90% were
excluded, (2) markers with call rates 90% were excluded, and (3) markers with allele distri-
butions deviating from Hardy-Weinberg equilibrium (HWE) in controls (p< 1× 10−5) were
also excluded. A total 126,270 markers (101,692 of them with a MAF > 0.1%) passed QC and
were included in the analysis.
The same ImmunoChip platform was used for White and African American populations.
The genotyping rate was 0.988 in the African American sample while the genotyping rate was
0.998 among Whites.
GWAS analysis: We also performed a genome-wide genotyping of both African Americans
and Whites. African Americans were genotyped on the Illumina Omni2.5 BeadChip that fea-
tures ~2.5 million markers capturing variants down to MAF 2.5% and covers, in particular,
African genetic diversity. The same exact individuals that were successfully genotyped on
ImmunoChip were successfully genotyped on this platform. The genotyping rate after QC was
0.993 in African American population. The quality control for African Americans also
included principal component analysis as implemented in SNP & Variation Suite v.7 (Golden
Helix). The first three principal components were derived for each individual from the African
American sample along with HapMap Phase 2 samples as reference populations. Individuals
deviating for more than 6 SDs from the African ancestry cluster centroid were discarded from
further analysis. We also excluded individuals deviating more than 4 standard deviations from
the cluster centroid. Finally, we excluded duplicate and closely related samples (PIHAT 0.5).
The genome wide genotyping of the White populations has been described previously in
Radstake et al (2010) [3]. In brief, Hap550K-BeadChip was used for US Whites and Illumina
HumanCNV370K BeadChip in Spanish Whites.
For the SNP-level analysis the association statistics was computed via logistic regression
including sex as a covariate for each dataset. For the White samples, meta-analysis combining
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odds ratios (OR) and standard errors (SE) of individual datasets (US and Spanish, so that the
controls in each set were from the same country as cases) was performed by means of the
inverse-variance method under the assumption of a fixed effect as implemented in PLINK
v.1.07. [13].
For the gene-level analysis we used Versatile Gene-based Association Study (VEGAS) [14].
We used VEGAS because it outperforms similar methods by sensitivity and specificity from
simulation studies [15]. VEGAS can be applied to the data generated by any GWAS designs,
including family-based GWAS, meta-analyses of GWAS and DNA-pooling-based GWAS. The
test uses information from the complete set of markers within a gene. To account for linkage
disequilibrium between markers VEGAS uses simulations from the multivariate normal distri-
bution. VEGAS assigns SNPs to autosomal genes according to positions on the UCSC Genome
Browser hg18 assembly. In order to capture regulatory regions and SNPs in LD, the gene
boundaries are defined as ±50 kb of 5’ and 3’ UTRs. VEGAS assigned SNPs genotyped by
ImmunoChip to 11,501 genes. Assuming independence of the gene level tests, the threshold
for statistical significance in the analysis of ImmunoChip in Whites was set to be 4.35x10-6,
and at 2.8x10-6 for the analysis of GWAS data [14]. However, since this threshold is likely to be
conservative given the overlap between genes, we report findings with p-values <10−5. Also,
since the sample size for African Americans was limited, for this population we present find-
ings with the p-value below 10−3, acknowledging that this is a study limitation and that the
analysis is exploratory and is in need for further validation. We use the term “nominal signifi-
cance” to denote p-values in the range of 0.05 to 10−3, interpreting them as weak evidence of
association. We excluded HLA region from the analysis because it is universally significant.
We used PathwayStudio [16] to build a pathway of known and novel SSc risk-associated
genes. The PathwayStudio uses text mining to identify reported interactions between genes
and build a network based on the known interactions.
Results
ImmunoChip analysis
Table 1 shows results from the gene-level and SNP-level analyses for 19 non-HLA genes previ-
ously shown to be associated with SSc in Whites [1–8, 17, 18]. Out of 19 known SSc genes, all
except for SCHIP1, IRF8, and CD247were nominally significant in the gene-level analysis in
Whites. IRF5, STAT4, and TNPO3were significant in both the SNP- and gene-level analyses
among Whites.
In the gene-level analysis of clinical phenotypes (S1 and S2 Tables) and antibody subsets
(S3 and S4 Tables), STAT4 was significant for lcSSc and ACA+ patients and TNPO3 in ATA
+ patients. Of the 19 genes examined, only TNFAIP3 was nominally significant in African
Americans in the gene-level analysis.
Table 2 shows non-HLA genes with the p-values below 10−5 in the gene-level analysis for
Whites (excluding those already established in Whites), with the addition of p-values for these
genes in African Americans. The genes with the p-values below 4.35x10-6 are shown in bold.
One gene out of four significant at this level in Whites, namely FCGR2C, was also nominally
significant in African Americans. PINX1, which was only borderline significant in Whites, also
showed a nominal significance in African Americans. Additionally, nominally significant
SNPs where observed in STAT1 and SCT genes and in the borderline significant EXOC2 in the
analysis of African Americans (Table 2), even though these genes did not reach significance in
the gene-level analysis in that population.
The top genes identified for clinical phenotypes and autoantibody subsets are shown in
S1–S4 Tables, in the left portion for the gene-level analyses based on ImmunoChip. FCGR2C,
Gene-level association analysis of systemic sclerosis
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STAT1, and FCGR3Bwere significant in lcSSc, although FCGR2C and FCGR3B shared the
most significant SNP rs455499 and the gene-level p-value for FCGR2Cwas more significant
(S1 Table). In dcSSc, three genes (IL34, ABBA-1, and VAC14) were identified as significant,
although they shared the most significant SNP rs11640251 and IL34 had the best p-value in the
gene-level analysis (S2 Table). In ACA+ patients, in addition to STAT4, six genes (FCGR2C,
Table 1. Results of the gene-level analyses for known genes associated with risk of SSc in Whites and African Americans, based on ImmunoChip.
Whites African Americans
Gene Chr NSNPs P-value Top SNP Top SNP P-value NSNPs P-value Top SNP Top SNP P-value
STAT4 2 113 2.00E-09 rs10174238  4.65E-13 108 0.105 rs1551443  0.0106
TNPO3 7 102 3.00E-08 rs17340351  2.39E-10 105 0.314 rs1495461 § 0.0574
IRF5 7 49 2.00E-06 rs12534421  7.42E-10 53 0.211 rs1495461 ‡ 0.0574
TNIP1 5 124 4.90E-05 rs10463312  4.87E-06 156 0.189 rs2277940 § 0.00742
IL12RB2 1 69 5.40E-05 rs2201584  1.29E-06 84 0.921 rs11209045  0.0418
BLK 8 176 1.43E-04 rs2409781  2.99E-08 172 0.552 rs11250139  0.0244
ITGAM 16 53 1.96E-04 rs1143683 † 5.70E-05 67 0.337 rs4561481  0.00771
IL12RB1 19 42 0.001144 rs2305743  7.23E-05 48 0.215 rs426132  0.0733
TNFAIP3 6 45 0.00145 rs892999  0.0103 69 0.00613 rs10223636  0.00203
IL12A 3 110 0.00248 rs4679867  8.79E-05 141 0.741 rs4679867  0.0508
TYK2 19 60 0.00363 rs2304256 † 1.61E-04 63 0.758 rs8108709  0.1514
ATG5 6 54 0.0076 rs11758079  0.00276 62 0.272 rs4946731  0.0083
CSK 15 8 0.0129 rs6495122 § 1.96E-05 9 0.787 rs8033381  0.299
JAZF1 7 96 0.0325 rs6971086  5.64E-04 112 0.844 rs3823946  0.0122
PXK 3 180 0.0397 rs7626140  0.00699 187 0.755 rs9870786  0.0177
DNASE1L3 3 84 0.0464 rs4681786  3.09E-04 93 0.597 rs9843169  0.0177
CD247 1 5 0.0821 rs2056626  0.00541 8 0.467 rs10918695  0.211
IRF8 16 24 0.0986 rs10863202  0.0165 28 0.518 rs11642456  0.129
SCHIP1 3 81 0.174 rs1675497  0.00108 77 0.449 rs17753641  0.0543
Intronic SNP
intergenic SNP
†coding SNP
§3’ downstream SNP
‡5’ upstream SNP
https://doi.org/10.1371/journal.pone.0189498.t001
Table 2. Comparison of novel candidate genes (at p<4.35x10-6 indicated in bold) and suggestive genes (4.35x10-6<p<10−5) detected in Whites to the corresponding
statistics in African Americans in the gene level analysis, based on ImmunoChip.
Whites African Americans
Gene Chr NSNPs P-value Top SNP Top SNP p-value NSNPs P-value Top SNP Top SNP p-value
STAT1 2 60 <1.00E-06 rs11893432  4.01E-11 58 0.581 rs16833197  0.0195
FCGR2C 1 26 3.00E-06 rs4554699  2.72E-08 24 0.0158 rs17411858  0.00497
NIPSNAP3B 9 3 4.00E-06 rs3780540  7.79E-04 4 0.551 rs3780540  0.31
SCT 11 34 4.00E-06 rs4963128  6.72E-05 52 0.691 rs10902178  0.0456
SERBP1 1 48 6.00E-06 rs3790569  5.61E-05 61 0.855 rs11807749  0.0682
PINX1 8 200 8.00E-06 rs17152571  1.46E-05 210 0.0283 rs17152345  6.61E-04
EXOC2 6 15 8.00E-06 rs908026  2.79E-05 21 0.382 rs7761186  0.0396
Intronic SNP
intergenic SNP
https://doi.org/10.1371/journal.pone.0189498.t002
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SRCAP, PHKG2, LOC90835,RNF40, and FCGR3B) reached significance in the ImmunoChip-
based gene-level analysis, but the middle four genes shared the most significant SNP rs71889
27 and SRCAP showed the best gene-level p-value (S3 Table), and FCGR2C and FCGR3B also
shared the most significant SNP rs455499. Of these two genes, FCGR2C showed a more signifi-
cant gene-level p-value like in the case of the lcSSc phenotype. Among ATA+ patients, in addi-
tion to TNPO3,C16orf68,P2RX1,C3orf25, IFT122, and MBD4 reached significance in the
gene-level analysis, with the last three genes sharing the same most significant SNP rs2307293
(S4 Table).
In the reverse approach we selected top non-HLA genes most significant in African Ameri-
cans (p<10−3) based on the gene level analysis (Table 3; 13 genes but only 9 independent
regions, due to the gene overlap).
Of these genes, only UNC5C (p = 5.57x10-4) and CLEC16A (p = 0.0463) were nominally sig-
nificant in the gene-level analysis in Whites, and both these genes and PHF19 harbored a nom-
inally significant SNP in Whites (Table 3).
Among the 63 top genes (27 independent regions) selected based on SNP level analysis in
African Americans (S5 Table; genes with best SNP p-value<10−3 in African Americans), 16
genes (12 independent regions) were also nominally significant in Whites at the gene level and
42 genes harbored at least nominally significant SNPs in Whites (25 different SNPs due to
assignment of some SNPs to several genes at once). Since under the null hypothesis the expected
number of nominally significant SNPs in Whites is ~1 (27x0.05 = 1.3), the results suggest some
overlap in genetic susceptibility loci for SSc between Whites and African Americans.
GWAS data analysis
We performed similar analyses also based on the GWAS genotyping which was, however, per-
formed on different platforms in Whites and African Americans, and this made the results less
Table 3. Genes most significant (at p<10−3) in African Americans in the gene-level analysis and the results for these genes in Whites, based on ImmunoChip.
African Americans Whites
Gene Chr NSNPs P-value Top SNP Top SNP p-value NSNPs P-value Top SNP Top SNP p-value
SCN4B 11 4 1.20E-05 rs868344 ǁ 4.04E-03 4 0.544 rs671111 § 0.291
SCN2B 11 4 1.50E-05 rs868344 § 4.04E-03 3 0.687 rs671111 § 0.291
MRPL28 16 1 6.20E-05 rs743961 ‡ 6.72E-05 1 0.0863 rs3848368  0.0856
TMEM8 16 1 6.20E-05 rs743961  6.72E-05 1 0.105 rs3848368  0.0856
NME4 16 1 6.90E-05 rs743961 ‡ 6.72E-05 1 0.0869 rs3848368  0.0856
DECR2 16 1 7.50E-05 rs743961 ‡ 6.72E-05 1 0.0836 rs3848368  0.0856
UNC5C 4 8 1.22E-04 rs7697199  6.20E-05 6 5.57E-04 rs17381177  7.84E-04
RAB11FIP3 16 2 2.96E-04 rs743961 ‡ 6.72E-05 1 0.358 rs3785301  0.338
PLCG2 16 5 4.97E-04 rs4325546  3.15E-03 8 0.601 rs3936112  0.0874
CLEC16A 16 329 5.29E-04 rs1646066  5.39E-04 355 0.0463 rs16957854  0.00169
ABCB4 7 24 5.77E-04 rs17149601  2.16E-04 17 0.271 rs17149512 ǁ 0.083
TCERG1 5 1 7.61E-04 rs10056189  7.31E-04 1 0.135 rs10056189  0.171
PHF19 9 74 8.09E-04 rs1008382  1.32E-04 61 0.721 rs388040  0.0426
ǁ 3’UTR SNP
§3’ downstream
‡5’ upstream
intronic SNP
intergenic SNP
https://doi.org/10.1371/journal.pone.0189498.t003
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comparable. The results are presented in S6–S11 Tables. In brief, among the genes previously
identified in Whites, in addition to TNFAIP3, ATG5 showed a nominal significance in the
gene-level analysis in African Americans, potentially due to a denser coverage of this gene (81
vs 62 SNPs) on the 2.5 M Omni platform than on ImmunoChip (S6 Table).
Beyond the genes previously established as associated with SSc in Whites, only one gene,
TMEM175, showed a borderline significant association in the gene-level analysis in Whites
(p = 3.0x10-6) in GWAS. Its most significant SNP rs2290405 was shared with two other genes
(SLC26A1 and DGKQ; S7 Table). The analysis of the corresponding genes in the GWAS data
in African Americans did not detect gene-level significance for these genes but TMEM175 har-
bored a nominally significant SNP rs11946340 unlike the other two neighboring genes.
In the analysis of clinical phenotypes and autoantibody subsets, out of already established
SSc susceptibility genes, IRF5, TNPO3, and IRF8 were significant in lcSSc patients. There were
also seven newly identified genes, of which four (DGKQ, IDUA, TMEM175, and SLC26A1)
shared the same most significant SNP rs11724804; of these, DGKQ showed the best gene-level
p-value. IRF4, CCDC104, and TLR10were also significant. Notably all these genes were at least
nominally significant in the ImmunoChip-based gene-level analysis, except for CCDC104
which is not on ImmunoChip (S1 Table). In dcSSc, in addition to IRF5 and TNPO3,CPSF4
and ATP5J2 showed significant p-values in the gene-level analysis; they shared the same most
significant SNP rs10235235, and CPSF4 was more significant in the gene-level analysis. Except
for IRF5 and TNPO3, no gene reached statistical significance in the ACA+ subset in the
GWAS-based gene-level analysis. In the ATA+ subset, TLR10 and TLR1, sharing the same
most significant SNP rs10024216, were significant (both reached only nominal significance in
the ImmunoChip-based gene-level analysis) (S4 Table).
In the reverse analysis, considering the top genes identified in the gene-level analysis in
African Americans (12 non-HLA genes but 11 regions due to the gene overlap, S8 Table),
none of the corresponding genes was even nominally significant in Whites but 6 genes har-
bored nominally significant SNPs. Among the genes identified in the GWAS SNP-level analy-
sis on African Americans as harboring most significant SNPs (p<10−3; 488 such genes but
only 308 independent regions because of the gene overlap), 311 genes (255 independent
regions) also harbored at least nominally significant SNPs in Whites. Eight genes (SLC2A13,
NRG3, SLC10A7, MKL1, DZIP1L, C8orf58,KIAA1967, and HDAC1; seven independent
regions, C8orf58 and KIAA1967 representing the same region) were nominally significant in
both Whites and African Americans in the gene-level analysis. The results are presented in S9
Table (a). Five SNPs—rs2994241 in C10orf27/ADAMTS14, rs6025407 in BMP7, rs6796265 in
OSBPL10, rs7734699 in MRPS27, and rs6075784 in STK35 –were nominally significant in both
Whites and African Americans. These five SNPs are marked in green in S9 Table (a), and their
risk effects are shown in S9 Table (b).
We also catalogued genes identified in African Americans either in GWAS or ImmunoChip
gene-level analysis (S10 Table), or by the top SNP p-value (with p<10−3) (S11 Table). In the
few cases where the same SNP was top in both GWAS and ImmunoChip analyses, a slight p-
value variation is explained by the QC procedures that eliminated different number of individ-
uals from the ImmunoChip versus GWAS analysis.
Genes for SSc and other autoimmune diseases are enriched by the immune response genes
[19–21]. One can expect, therefore, that SSc genes will be often involved in direct interactions.
We used PathwayStudio to build an interaction network of known as well as 6 novel candidate
genes (both significant and suggestive) (Table 3) identified by the gene-level analysis. Such net-
works may be useful by providing guidance to explore biological mechanisms underlying SSc
risk. We found that two suggestive candidates, namely EXOC2 and PINX1, interact with
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known genes associated with risk of SSc. The EXOC2 protein has been shown to bind LST1
[22], and PINX1 and STAT1 show protein/protein interaction [23] (S1 Fig).
Discussion
We identified 4 novel candidate genes (STAT1, FCGR2C,NIPSNAP3B, and SCT) significantly
associated and 4 genes (SERBP1, PINX1, TMEM175 and EXOC2) suggestively associated with
SSc in a gene level analysis in Whites. Some of these genes have been shown to be directly
involved in immune response. For example, FCGR2C encodes a member of low-affinity immu-
noglobulin gamma Fc receptors. FCGR2C is found on the surface of many immune response
cells. The gene encodes a transmembrane glycoprotein involved in phagocytosis and clearing
of immune complexes. A suggestive novel gene, SERBP1, encodes a B-cell antigen, shown to
predict anti-tumor immune response [24]. Another suggestive gene, EXOC2, is associated with
innate immunity and has been shown to play a role in susceptibility to Crohn’s disease [25].
We note that the suggestive signal at EXOC2 overlaps with the signal at IRF4 previously
described in the cross-disease meta-GWAS of SSc and rheumatoid arthritis [26], which points
at the importance of this region in autoimmune conditions. This gene harbored a SNP rs908
026 with a relatively strong statistical evidence for risk association (P = 2.8x10-5). Risk-associ-
ated SNPs were observed in other gene-level candidates as well. For example, rs11893432
(STAT1 gene; p = 4.01x10-11) and rs4554699 (FCGR2C gene; p = 2.7x10-8) were significant at
the GWAS level. The most significant SNPs in other novel candidates were: rs2290405 in
TMEM175 (p = 1.82x10-6), rs17152571 in PINX1 gene (P = 1.5x10-5), rs3790569 in SERBP1
gene (P = 5.6x10-5), rs4963128 in SCT gene (P = 6.7x10-5), and rs3780540 for NIPSNAP3B
gene (P = 7.8x10-5). We admit that a further revalidation in an independent study of SSc in
Whites is necessary.
Out of the 19 genes that were previously identified as harboring SSc susceptibility SNPs in
Whites, only TNFAIP3 was nominally significant in the gene-level analysis in African Ameri-
cans. Previously, we showed that SNPs of TNFAIP3 had a strong association with expression of
matrix metalloproteinase 1 and 3 in fibroblasts of ethnically diverse patients in response to sil-
ica particle stimulation [27].
Several factors could have contributed to the absence of an association in African Ameri-
cans for genes found in Whites. First, the distribution of clinical phenotypes is markedly differ-
ent in the two populations, with a considerably higher proportion of the diffuse phenotype
among African Americans (69%) as compared to Whites (31%). Our previous publication [6]
shows differences in the genetic architecture of SSc clinical phenotypes. Thus clinical pheno-
type-specific analyses by ethnic group would be most meaningful, because they would allow
for more accurate racial comparisons. Unfortunately, the limited number of African American
participants precluded the phenotype or autoantibody subset analyses in the current study.
Second, the power of the analysis in the African Americans was limited because of the sam-
ple size. Moreover, the power of the analysis depends not solely on the sample size but also on
the risk allele frequency. S9 Table (b) exemplifies that there is a considerable variation in the
allele frequencies between the two populations, which could have contributed to the inter-eth-
nic differences. Third, even if the effects of causal SNPs are similar across ethnicities, GWAS-
identified tagging SNP alleles can be in the opposite linkage phases in two given ethnic groups.
This will result in the opposite effects of the tagging SNPs identified as significant in both Afri-
can Americans and Whites, and the data in S9 Table (b) suggest exactly that: some SNPs iden-
tified as nominally significant have very similar frequencies but the opposite direction of the
effect in African Americans and Whites. It is also possible that the causal SNPs are different in
different ethnicities although the susceptibility genes are the same. A gene-level analysis of
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dense genotyping data, such as ours, should be able to capture the susceptibility genes even in
case of the ethnic heterogeneity for causal alleles, unless a given ethnicity lacks causal variants
in a potential susceptibility gene, in which case the gene will not be associated with disease in
that ethnic group. The genes listed in Table 2, except for NIPSNAP3B, are densely SNP-geno-
typed in both Whites and African Americans. Thus it is not very likely that an individual SNP
being poly- versus monomorphic has led to the loss of an association. For NIPSNAP3B, the top
SNP in both populations was the same, rs3780540, and the MAF was actually higher in African
Americans (0.116) than in Whites (0.0179), yet it was only significant in Whites.
An interaction network built using Pathway Studio detected a large number of interactions
between genes associated with SSc risk. Genes with the largest number of interactions include
ITGAM,AIF1, STAT1, IL12RB2; these genes form hubs of the network and are likely to be
master genes in biological control of SSc risk. Two suggestive candidates, EXOC2 and PINX1,
are also part of this network.
As mentioned before, limitations of this study are (1) a relatively small sample size for Afri-
can Americans, which prevents us from drawing any definite conclusion concerning the hith-
erto unresolved issue whether the same genes/SNPs influence SSc risk in different ethnic
groups, and (2) the absence of independent validation cohorts. We acknowledge, therefore,
that our analyses should be considered exploratory. Nevertheless, we carried out such analyses
because the data are unique and their analysis may be important for the understanding of the
role of ethnicity in the genetic architecture of SSc.
The results of our exploratory analysis might suggest that there exist both trans-racial and
race-specific susceptibility loci for SSc, but further validation by independent studies, in partic-
ular a properly powered SSc GWAS in African Americans that allows subset analyses, is neces-
sary to answer this question.
Conclusions
A gene-level analysis focusing on the data generated by the ImmunoChip platform was per-
formed on White and African American SSc patients. This study represents the first report of
genetic analysis of African Americans with SSc. The gene-level analysis identified four novel
candidate genes (STAT1, FCGR2C,NIPSNAP3B, and SCT) significantly associated with SSc in
Whites. As an exploratory analysis we compared the results in Whites with those generated
from African Americans. There was weak evidence of existence of SSc susceptibility loci that
showed effects in both Whites and African Americans. Our findings need to be validated by
independent studies, particularly due to the limited sample size of African Americans. The
clinical phenotype and autoantibody subset analyses for Whites are also presented, but future
studies should compare the phenotype- and autoantibody-stratified analyses in Whites and
African Americans.
Supporting information
S1 Table. A catalogue of genes identified for limited SSc in Whites as harboring SNPs at
p<10−5 in either ImmunoChip or GWAS data.
(XLSX)
S2 Table. A catalogue of genes identified for diffuse SSc in Whites as harboring SNPs at
p<10−5 in either ImmunoChip or GWAS data.
(XLSX)
Gene-level association analysis of systemic sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0189498 January 2, 2018 9 / 12
S3 Table. A catalogue of genes identified for ACA-positive SSc in Whites as harboring
SNPs at p<10−5 in either ImmunoChip or GWAS data.
(XLSX)
S4 Table. A catalogue of genes identified for ATA-positive SSc in Whites as harboring
SNPs at p<10−5 in either ImmunoChip or GWAS data.
(XLSX)
S5 Table. The top genes selected based on SNP level analysis (p<10−3) of ImmunoChip
data in African Americans.
(XLSX)
S6 Table. The comparison of results of the gene-level analysis for Whites and African
Americans for the genes previously shown as associated with SSc risk in Whites, based on
GWAS data.
(XLSX)
S7 Table. Top novel genes identified by the gene-level analysis of GWAS data in Whites,
with the comparative results from GWAS in African Americans.
(XLSX)
S8 Table. The top genes identified in the gene-level analysis of GWAS data in African
Americans, with the comparative results in Whites.
(XLSX)
S9 Table. (a) The genes identified in the GWAS of African Americans as harboring most sig-
nificant SNPs (p<10−3), with the genes at least nominally significant at the gene level in both
African Americans and Whites shown at the top.(b). SNPs nominally significant in both Afri-
can Americans and Whites.
(XLSX)
S10 Table. A catalogue of genes identified in African Americans’ gene-level analysis of
either GWAS or ImmunoChip data.
(XLSX)
S11 Table. A catalogue of genes identified in African Americans as harboring SNPs at
p<10−3 in either GWAS or ImmunoChip data.
(XLSX)
S1 Fig. The interaction network for known and novel candidate genes detected by the
gene-level analysis.
(DOCX)
Acknowledgments
We are grateful for the excellent technical support of Julio Charles, Marilyn Perry, Tony Mat-
tar and Deepthi Nair. We also thank the subjects who generously provided the samples for
these studies.
Author Contributions
Conceptualization: Olga Y. Gorlova, Shervin Assassi, Christopher I. Amos, Javier Martin,
Maureen D. Mayes.
Gene-level association analysis of systemic sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0189498 January 2, 2018 10 / 12
Data curation: Yafang Li, Jun Ying, Wei V. Chen, Lara Bossini-Castillo, Elena Lopez-Isac,
Marialbert Acosta-Herrera, Peter K. Gregersen, Annette T. Lee.
Formal analysis: Olga Y. Gorlova, Yafang Li, Ivan Gorlov, Jun Ying, Wei V. Chen.
Investigation: Olga Y. Gorlova.
Resources: Shervin Assassi, John D. Reveille, Frank C. Arnett, Xiaodong Zhou, Virginia D.
Steen, Barri J. Fessler, Dinesh Khanna, Elena Schiopu, Richard M. Silver, Jerry A. Molitor,
Daniel E. Furst, Suzanne Kafaja, Robert W. Simms, Robert A. Lafyatis, Patricia Carreira,
Carmen Pilar Simeon, Ivan Castellvi, Emma Beltran, Norberto Ortego, Javier Martin, Mau-
reen D. Mayes.
Writing – original draft: Olga Y. Gorlova, Ivan Gorlov, Jun Ying, Wei V. Chen, Shervin
Assassi, John D. Reveille, Frank C. Arnett, Xiaodong Zhou, Lara Bossini-Castillo, Elena
Lopez-Isac, Marialbert Acosta-Herrera, Peter K. Gregersen, Annette T. Lee, Virginia D.
Steen, Barri J. Fessler, Maureen D. Mayes.
Writing – review & editing: Olga Y. Gorlova, Yafang Li, Ivan Gorlov, Jun Ying, Wei V. Chen,
Shervin Assassi, John D. Reveille, Frank C. Arnett, Xiaodong Zhou, Lara Bossini-Castillo,
Elena Lopez-Isac, Marialbert Acosta-Herrera, Peter K. Gregersen, Annette T. Lee, Virginia
D. Steen, Barri J. Fessler, Dinesh Khanna, Elena Schiopu, Richard M. Silver, Jerry A. Moli-
tor, Daniel E. Furst, Suzanne Kafaja, Robert W. Simms, Robert A. Lafyatis, Patricia Car-
reira, Carmen Pilar Simeon, Ivan Castellvi, Emma Beltran, Norberto Ortego, Christopher I.
Amos, Javier Martin, Maureen D. Mayes.
References
1. Bossini-Castillo L, Martin JE, Broen J, Simeon CP, Beretta L, Gorlova OY, et al. Confirmation of TNIP1
but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication
study. Ann Rheum Dis. 2013; 72(4):602–7. https://doi.org/10.1136/annrheumdis-2012-201888 PMID:
22896740; PubMed Central PMCID: PMC3887516.
2. Lopez-Isac E, Bossini-Castillo L, Simeon CP, Egurbide MV, Alegre-Sancho JJ, Callejas JL, et al. A
genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis
susceptibility. Arthritis Res Ther. 2014; 16(1):R6. https://doi.org/10.1186/ar4432 PMID: 24401602;
PubMed Central PMCID: PMCPMC3978735.
3. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, et al. Genome-wide
association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010;
42(5):426–9. https://doi.org/10.1038/ng.565 PMID: 20383147; PubMed Central PMCID: PMC2861917.
4. Allanore Y, Saad M, Dieude P, Avouac J, Distler JH, Amouyel P, et al. Genome-wide scan identifies
TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 2011; 7(7):
e1002091. https://doi.org/10.1371/journal.pgen.1002091 PMID: 21750679; PubMed Central PMCID:
PMCPMC3131285.
5. Bossini-Castillo L, Martin JE, Broen J, Gorlova O, Simeon CP, Beretta L, et al. A GWAS follow-up study
reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum
Mol Genet. 2012; 21(4):926–33. https://doi.org/10.1093/hmg/ddr522 PMID: 22076442; PubMed Central
PMCID: PMC3298110.
6. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, et al. Identification of novel genetic
markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association
strategy. PLoS Genet. 2011; 7(7):e1002178. https://doi.org/10.1371/journal.pgen.1002178 PMID:
21779181; PubMed Central PMCID: PMC3136437.
7. Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, et al. Immunochip analysis
identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet. 2014; 94(1):47–61. https://
doi.org/10.1016/j.ajhg.2013.12.002 PMID: 24387989; PubMed Central PMCID: PMC3882906.
8. Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, Castellvi I, et al. A systemic sclerosis and
systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol
Genet. 2013; 22(19):4021–9. https://doi.org/10.1093/hmg/ddt248 PMID: 23740937; PubMed Central
PMCID: PMC3766185.
Gene-level association analysis of systemic sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0189498 January 2, 2018 11 / 12
9. Ball RD. Designing a GWAS: power, sample size, and data structure. Methods in molecular biology.
2013; 1019:37–98. https://doi.org/10.1007/978-1-62703-447-0_3 PMID: 23756887.
10. van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV. Power in GWAS: lifting the curse of
the clinical cut-off. Molecular psychiatry. 2013; 18(1):2–3. https://doi.org/10.1038/mp.2012.65 PMID:
22614290.
11. Budhu A, Wang XW. Power play: scoring our goals for liver cancer with better GWAS study design.
Journal of hepatology. 2011; 54(4):823–4. https://doi.org/10.1016/j.jhep.2010.10.035 PMID: 21167853.
12. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, et al. Race and association with disease
manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma
Center and review of the literature. Medicine (Baltimore). 2013; 92(4):191–205. https://doi.org/10.1097/
MD.0b013e31829be125 PMID: 23793108; PubMed Central PMCID: PMCPMC4553970.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559–75.
https://doi.org/10.1086/519795 PMID: 17701901; PubMed Central PMCID: PMC1950838.
14. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A versatile gene-based test for
genome-wide association studies. American journal of human genetics. 2010; 87(1):139–45. https://
doi.org/10.1016/j.ajhg.2010.06.009 PMID: 20598278; PubMed Central PMCID: PMC2896770.
15. Wojcik GL, Kao WH, Duggal P. Relative performance of gene- and pathway-level methods as second-
ary analyses for genome-wide association studies. BMC genetics. 2015; 16:34. https://doi.org/10.1186/
s12863-015-0191-2 PMID: 25887572; PubMed Central PMCID: PMC4391470.
16. Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio—the analysis and navigation of molecular net-
works. Bioinformatics. 2003; 19(16):2155–7. PMID: 14594725.
17. Bossini-Castillo L, Lopez-Isac E, Martin J. Immunogenetics of systemic sclerosis: Defining heritability,
functional variants and shared-autoimmunity pathways. J Autoimmun. 2015; 64:53–65. https://doi.org/
10.1016/j.jaut.2015.07.005 PMID: 26212856.
18. Bossini-Castillo L, Lopez-Isac E, Mayes MD, Martin J. Genetics of systemic sclerosis. Semin Immuno-
pathol. 2015; 37(5):443–51. https://doi.org/10.1007/s00281-015-0499-z PMID: 26032405.
19. Broen JC, Coenen MJ, Radstake TR. Deciphering the genetic background of systemic sclerosis. Expert
review of clinical immunology. 2011; 7(4):449–62. https://doi.org/10.1586/eci.11.26 PMID: 21790288.
20. Agarwal SK. The genetics of systemic sclerosis. Discovery medicine. 2010; 10(51):134–43. PMID:
20807474; PubMed Central PMCID: PMC3803145.
21. Jin J, Chou C, Lima M, Zhou D, Zhou X. Systemic Sclerosis is a Complex Disease Associated Mainly
with Immune Regulatory and Inflammatory Genes. The open rheumatology journal. 2014; 8:29–42.
https://doi.org/10.2174/1874312901408010029 PMID: 25328554; PubMed Central PMCID:
PMC4200700.
22. Schiller C, Diakopoulos KN, Rohwedder I, Kremmer E, von Toerne C, Ueffing M, et al. LST1 promotes
the assembly of a molecular machinery responsible for tunneling nanotube formation. Journal of cell sci-
ence. 2013; 126(Pt 3):767–77. https://doi.org/10.1242/jcs.114033 PMID: 23239025.
23. Fleming JM, Ginsburg E, Oliver SD, Goldsmith P, Vonderhaar BK. Hornerin, an S100 family protein, is
functional in breast cells and aberrantly expressed in breast cancer. BMC cancer. 2012; 12:266. https://
doi.org/10.1186/1471-2407-12-266 PMID: 22727333; PubMed Central PMCID: PMC3464886.
24. Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, et al. Serologic markers of effective
tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer
research. 2010; 70(4):1344–55. https://doi.org/10.1158/0008-5472.CAN-09-3143 PMID: 20124481;
PubMed Central PMCID: PMC2852266.
25. McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, et al. Fucosyltransferase 2
(FUT2) non-secretor status is associated with Crohn’s disease. Human molecular genetics. 2010; 19
(17):3468–76. https://doi.org/10.1093/hmg/ddq248 PMID: 20570966; PubMed Central PMCID:
PMC2916706.
26. Lopez-Isac E, Martin JE, Assassi S, Simeon CP, Carreira P, Ortego-Centeno N, et al. Brief Report:
IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthri-
tis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis Rheumatol. 2016;
68(9):2338–44. https://doi.org/10.1002/art.39730 PMID: 27111665.
27. Wei P, Yang Y, Guo X, Hei N, Lai S, Assassi S, et al. Identification of an Association of TNFAIP3 Poly-
morphisms With Matrix Metalloproteinase Expression in Fibroblasts in an Integrative Study of Systemic
Sclerosis-Associated Genetic and Environmental Factors. Arthritis Rheumatol. 2016; 68(3):749–60.
https://doi.org/10.1002/art.39476 PMID: 26474180; PubMed Central PMCID: PMCPMC4767670.
Gene-level association analysis of systemic sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0189498 January 2, 2018 12 / 12
